What is ALS Phase 2 Study Lithium Carbonate?

Category: Others

false

See also: Clinical Trial

NCT00925847 is an open multicenter study of lithium in patients with amyotrophic lateral sclerosis. Other study ID names include: P080401.

Side effects

Side effects as an overall problem

Side effects as an overall problem
Severity Evaluations
Severe 0
Moderate 0
Mild 0
None 1

Commonly reported side effects and conditions associated with ALS Phase 2 Study Lithium Carbonate

Side effect Patients

Why patients stopped taking ALS Phase 2 Study Lithium Carbonate

Multiple reasons could be selected

Reason Patients
Other 1
See 1 patient who's stopped using ALS Phase 2 Study Lithium Carbonate

Duration

Stopped using ALS Phase 2 Study Lithium Carbonate

Duration Patients
1 - 2 years 1
Adherence
Adherence Evaluations
Always 1
Usually 0
Sometimes 0
Never taken as prescribed 0
Burden
Burden Evaluations
Very hard to take 0
Somewhat hard to take 0
A little hard to take 0
Not at all hard to take 1
Last updated:

1 patient evaluation for ALS Phase 2 Study Lithium Carbonate

Jul 20, 2011 (Started Jan 19, 2010)

  • Effectiveness
    Can't tell (for Participate in clinical trial)
  • Side effects
    None
  • Adherence
    Always
  • Burden
    Not at all hard to take
Dosage: 885 mcg Daily
Advice & Tips: It was a clinical trail, apart from getting the tablets - which were huge - out of the blister packs it was no bother...

  • 1 helpful mark
Last updated:
Showing 1 of 1 patient evaluation for ALS Phase 2 Study Lithium Carbonate